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ABSTRACT 
Background  and  aims:  Sorafenib  is  the  reference  therapy  for  advanced  Hepatocellular 
Carcinoma (HCC). No method exists to predict in the very early period subsequent individual 
response. Starting  from  the clinical experience in humans that subcutaneous metastases may 
rapidly change consistency under sorafenib and that elastosonography a new ultrasound based 
technique allows assessment of tissue stiffness, we investigated the role of elastonography in the 
very early prediction of tumor response to sorafenib in a HCC animal model.  
Methods:  HCC  (Huh7  cells)  subcutaneous  xenografting  in  mice  was  utilized.  Mice  were 
randomized  to  vehicle  or  treatment  with  sorafenib  when  tumor  size  was  5-10  mm. 
Elastosonography (Mylab 70XVG, Esaote, Genova, Italy) of the whole tumor mass on a sagittal 
plane with a 10 MHz linear transducer was performed at different time points from treatment 
start (day 0, +2, +4, +7 and +14) until mice were sacrified (day +14), with the operator blind to 
treatment. In order to overcome variability in absolute elasticity measurement when assessing 
changes over time, values were expressed in arbitrary units as relative stiffness of the tumor 
tissue in comparison to the stiffness of a standard reference stand-off pad lying on the skin over 
the tumor.  
Results: Sor-treated mice showed a smaller tumor size increase at day +14 in comparison to 
vehicle-treated (tumor volume increase +192.76% vs +747.56%, p=0.06). Among Sor-treated 
tumors,  6  mice  showed  a  better  response  to  treatment  than  the  other  4  (increase  in  volume 
+177% vs +553%, p=0.011). At day +2, median tumor elasticity increased in Sor-treated group 
(+6.69%, range –30.17-+58.51%), while decreased in the vehicle group (-3.19%, range –53.32-
+37.94%) leading to a significant difference in absolute values (p=0.034). From this time point 
onward, elasticity decreased in both groups, with similar speed over time, not being statistically 
different anymore. In Sor-treated mice all 6 best responders at day 14 showed an increase in 
elasticity at day +2 (ranging from +3.30% to +58.51%) in comparison to baseline, whereas 3 of   4
the  4  poorer  responders  showed  a  decrease.  Interestingly,  these  3  tumours  showed  elasticity 
values higher than responder tumours at day 0. 
Conclusions: Elastosonography appears a promising non-invasive new technique for the early 
prediction of HCC tumor response to sorafenib. Indeed, we proved that responder tumours are 
characterized by an early increase in elasticity. The possibility to distinguish a priori between 
responders and non responders based on the higher elasticity of the latter needs to be validated in 
ad-hoc experiments as well as a confirmation of our results in humans is warranted.   5
INTRODUCTION 
HepatoCellular Carcinoma (HCC) is one of the most common solid cancer worldwide, 
being the third cancer-related mortality cause.
1,2 Its incidence is increasing in Western countries 
mainly  due  to  the  high  prevalence  of  Hepatitis  C  Virus  (HCV)  infection.  Potential  curative 
therapies are currently offered to patients with very early/early stages HCC, according to the 
BCLC (Barcelona-Clinic Liver Cancer) staging system, which represent only one third of newly 
diagnosed  HCC  patients.
3  Only  supportive  care  were  offered  to  the  remaining  patients  until 
2007, when the clinical management of HCC radically changed thanks to the SHARP (Sorafenib 
HCC Assessment Randomized Protocol) trial that showed a survival benefit in patients with 
advanced HCC treated with sorafenib versus placebo.
2 Sorafenib is a multikinase inhibitor of 
Vascular  Endotelial  Growth  Factor  Receptor  2  (VEGFR2),  Platelet  Derived  Growth  Factor 
Receptor (PDGFR), Raf-1, B-Raf and c-kit among others,
4 currently adopted as standard care in 
patients with advanced HCC.
5 
Antiangiogenic treatments, such as sorafenib, are addressed to block signals related to 
neoangiogenesis rather than to provide a direct cell killing effect. Since that they can be effective 
even in absence of tumor shrinkage, WHO (World Health Organization) and RECIST criteria 
cannot  be  used  in  this  setting.
6,7  These  criteria,  which  are  based  on  dimensional  evaluation 
following therapy, were amended in 2000 by a panel of experts on HCC during the European 
Association for the Study of the Liver (EASL) conference. The new suggested concept aimed to 
take into account the intratumoral necrosis induced by the treatment, rather than the reduction in 
tumour size. Response to treatment was then evaluated measuring the reduction in viable tumor 
area, assessed using contrast-enhanced radiological techniques. A modified version of RECIST 
criteria was created in 2008 under the auspices of the American Association for the Study of 
Liver Disesase (AASLD) (m-RECIST) in order to provide a common approach for designing 
clinical trials and to standardize imaging techniques for response assessment.
8 Even if promising 
results are available concerning contrast-enhanced ultrasonography and its quantification,
9,10 up   6
to  now  only  “heavy”  radiological  techniques  (contrast-enhanced  computed  tomography  and 
magnetic resonance) are commonly accepted in this setting. 
  Elastosonography is an ultrasound-based technique able to evaluate in vivo the elastic 
proprieties of a tissue measuring the strain in response to an external compression. This method 
has  been  successfully  employed  in  superficial  tissues,  such  as  thyroid  or  breast,  for  the 
differentiation  between  benign  and  malignant  nodules
11-14  whilst  its  role  the  diagnosis  of 
HCC
15,16 and in the evaluation of hepatic fibrosis remains controversial.
17,18  
  A softening of a tumoral mass during therapy  is often the first objective evidence of 
tumour response.
19,23 So far, only subjective sensings are described and no data are available 
concerning an objective quantification of changes in tumour consistence. Thus, the present study 
aims to evaluate whether elastosonography may be a useful tool in the response assessment to 
antiangiogenic treatment in an experimental model of HCC. 
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MATERIALS AND METHODS 
Experimental model 
Human cell line Huh7, kindly provided by Dr. Porretti, was maintained and expanded using 
standard  cell  culture  technique  in  high  glucose  Dulbecco’s  Modified  Eagle  Medium 
supplemented  with  L-glutamine,  1%  ampicillin/amphotericin  B  and  10%  fetal  bovine  serum 
(Gibco, Italy). The model was established by subcutaneous injection of 5x10
6 cells suspended in 
sterile phosphate-buffered saline (Gibco, Italy) for a total volume of 0.2 mL per injection into the 
right flank of 6-8 weeks old female mice (Charles River, Calco, Italy). During the experiments, 
the  mice  were  maintained  with  regular  mouse  chow  and  water  ad  libitum  in  a  temperature-
controlled room under a 12-hour light/dark circle and specific pathogen-free circumstances. Mice 
were randomized to vehicle or treatment with sorafenib (BAY 43-9006; Bayer, Germany) at a 
dosage of 62 mg/Kg by oral gavage daily. Sorafenib was formulated as previously described.
24 
Growth of established xenografts was monitored at least twice weekly by ultrasound. Mice were 
divided into 2 groups: in group A, treatment started when tumor reached 5-10 mm in diameter 
and lasted for 14 days whereas, in group B, treatment started when tumor reached 12-18 mm in 
diameter and lasted for 2 days. The internal animal welfare committee approved the experimental 
protocol. 
 
Ultrasound and elastosonography imaging experiments 
Ultrasound examinations were performed using a MyLab70 XVG (Esaote, Genova, Italy) 
equipped with a 4-13 MHz probe. Mice were anesthetized intraperitoneally with 0.2 mL of a 
solution constituted by one part of ketamine 10% (Ketavet, Intervent Production s.r.l.), one part 
of  xylazine  20  mg/mL  (Rompun,  Bayer)  and  eight  parts  of  sterile  water.  The  anesthetized 
animals were placed on a heating support in order to keep constant the temperature for all the 
duration of the experiment. For B-mode examinations, the tumours were covered with ultrasound   8
gel.  Volume  was  calculated  using  the  formula:  height  x  width  x  thikness/2  measured  by 
ultrasound, considering the respective biggest diameter.  
Elastosonography  was  performed  by  a  single  operator  by  selecting  “ElaXto  Ratio” 
modality  on  the  ultrasound  system  screen.  This  technique  allows  the  differentiation  among 
tissues,  representing  different  deformations  subsequent  to  a  manual  strain  applied 
perpendicularly  by  the  operator  as  colour-coded  images.  The  same  condition  of  brightness, 
contrast, intensity and gain were used in all the examinations. For elastosonography, the probe 
was placed on a pad by interposing a thin quantity of ultrasound gel between the probe and the 
pad and between the pad and the tumour, paying attention in scanning the biggest section of the 
tumour. The pad was used to correlate the elasticity of the tumor with a reference elasticity. 
Results were considered reliable when the warning light spring on the screen turned from grey to 
green,  which  meant  an  adequate  compression  level.  The  equipment  displays  two  images 
simultaneously: the conventional B-mode image and an image where the Region Of  Interest 
(ROI) appears in a chromatic scale that identifies different levels of elasticity. The software 
requires to identify two ROIs (drawn by a second operator), one including the almost totality of 
the pad surface (ELX1) and the other surrounding the entire tumour surface (ELX2) (Fig.1).   9
 
Figure  1.  ElaXto  modality.  Two  ROIs  have  to  be  drawn  on  the  colour-coded  image  by  the 
operator. ELX2/1 value (the ratio between the ROI of the tumour and that of the pad) is provided 
in real-time as well as the histogram representing the distribution of the colours in each ROI. 
 
Results  are  provided  in  real  time  by  dividing  ELX2  for  ELX1.  Resulting  values  are 
directly proportional to the elasticity of the tumor compared to the pad. Also the histogram of the 
distributions  of  the  colours  inside  the  ROIs  is  provided.  Three  valid  measurements  were 
performed in each tumor and the mean value was used for following analyses. All the procedure 
lasted approximately 2 minutes per mice. 
The same procedure protocol was repeated at different time points starting from the beginning of 
the treatment (0, +2, +4, +7 and +14 days in group A and 0 and +2 in group B). 
   10
Necropsy 
At day +14 for group A and at day +2 for group B after the last measurement and still 
under  anaesthesia,  animals  were  euthanized  by  0.1  mL  of  a  solution  of  embutramide, 
mebezonium  iodide  and  tetracaine  hydrochloride  (Tanax,  Intervet  Italia  s.r.l.).  A  slice  of  all 
group A tumours were frozen in liquid nitrogen vapour and stored at –80°C. 
 
Western-Blot  
Two  monoclonal  antibodies  (55B11  and  20G11,  Cell  Signaling  Technology,  Inc. 
Danversa, MA, USA) against VEGFR2 (diluted at 1:1000) and phospho-p44/42 MAPK (Erk1/2; 
Thr202/Tyr204) (diluted at 1:1000) were incubated separately for 16 hours at 4°C. A horseradish 
conjugated  secondary  antibody  (labeled  polymer-HRP  antimouse,  Envision  system  DAKO 
Cytomation, Carpinteria, CA, USA) was incubated for 45 minutes at room temperature and the 
corresponding band was revealed using the enhanced chemoluminescence method (Amersham, 
UK). Digital images of autoradiographies were acquired with Fluor-S MultiImager (Bio-Rad, 
Hercules, CA, USA) and band signals were acquired in the linear range of the scanner using a 
specific  densitometric  software  (Quantity-one,  Bio-Rad,  Hercules,  CA,  USA).  Images  were 
calibrated  against  a  reference  autoradiography  and  given  in  relative  density  units.  After 
autoradiography acquisition, the membranes were stripped and reprobed for two hours at room 
temperature with anti b-actin antibody (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA) to 
normalize protein loading. A ratio between VEGFR2 or phospho-ERK and b-actin corresponding 
bands was used to quantify the levels of each protein (normalized value). This ratio was divided 
by b-actin levels of HuH7 line in each blot in order to compare the results in different running 
blot (absolute value).   
   11
Statistical evaluation 
Data  are  presented  as  median  and  min-max  in  round  brackets.  Differences  between 
groups were compared using the Mann-Whitney test (2-tailed). Differences among different time 
points in the same group were compared using the Wilcoxon signed Rank test. Percentage delta 
was  calculated  using  the  formula  [(final  value-starting  value)/starting  value]%.  P<0.05  was 
considered significant. Statistical analysis was performed using SPSS 16.0 (Chicago Il, USA).  
   12
RESULTS 
Group A. 
Group A comprised 19 mice, 10 in the treatment group and 9 in the vehicle group. Tumor 
volume at day 0 was 151.09 mmc (66.83-602.58). At day +14, tumor volume was 608 mmc 
(333.3-1799.88) in treatment group and 893.43 mmc (218.67-1996.70) in vehicle group with a 
growth percentage delta of 192.76% (84.72-739.48) in treatment group and 747.56% (73.47-
2887.62) in vehicle group. 
Elasticity  tended  to  increase  in  the  treatment  group  at  day  +2  compared  to  day  0  while  a 
reduction was evident in the vehicle group (Table 1). ELX2/1 values at day +2 were statistically 
different between the two groups (p=0.034). 
 
ELX2/1  Treatment group  Vehicle group  p 
day 0  1.31 (1.07-1.97)  1.25 (1.07-1.81)  n.s. 
day +2  1.38 (1.15-1.99)  1.14 (0.75-1.56)  0.034 
day +4  1.31 (1.12-1.87)  1.16 (1.03-1.44)  n.s. 
day +7  1.25 (1.08-1.79)  1.19 (0.94-1.59)  n.s. 
day +14  1.16 (0.70-1.74)  1.09 (0.75-1.35)  n.s. 
Table 1. ELX2/1 values in the treatment and in the vehicle group. A difference between the two 
groups was evident only at day +2 (p=0.034). 
 
In treatment group, after an early increase from day 0 to day +2, elasticity decreased from day +2 
to day +14 (Fig.2). Indeed, ELX2/1 values at day +14 were statistically different compared to 
day 0 (p=0.028).  
In vehicle group, after an early decrease from day 0 to day +2, then elasticity remained quite 
constant over time without statistical difference between day 0 and day +14 ELX2/1 values.   13
 
Fig.2. ELX2/1 trend over time in the treatment group (green line) and in the vehicle group (blue 
line). A statistical difference was evident at day +2 between the two groups (p=0.034), showing a 
higher elasticity of tumours in the treatment group with respect to the vehicle group. ELX2/1 
tended to decrease in the treatment group comparing day 0 and day +14 (p=0.028). 
 
A  sub-analysis  was  performed  in  treatment  group  dividing  tumours  with  respect  to 
growth percentage delta. If the growth percentage delta was <200%, tumours were considered as 
responder (6 cases, ranging from 85% to 199%) whilst non responder if the growth percentage 
delta was >350% (4 cases, ranging from 382% to 739%).  
Volume at day +14 was 523.56 (333.33-1799.88) in the responder group and 761.69 (474.30-
1154.16)  in  the  non  responder  group.  ELX2/1  was  1.31  (1.07-1.97)  at  day  0. All responder 
tumours showed an increase in ELX2/1 from day 0 to day +2. Among non responder tumours, 3 
out of 4 showed at D0 higher values than responder tumours. Furthermore, a decrease of ELX2/1 
was evident in these 3 cases whilst an increase was seen in the remaining one (Table 2 and 
Fig.3).    14
 
  ELX2/1 at D0  ELX2/1 at D2  ELX2/1 %Delta 
Responder (R) tumours  1.36  1.54  13.8 
  1.25  1.99  58.5 
  1.27  1.38  8.9 
  1.27  1.33  4.5 
  1.35  1.52  12.8 
  1.11  1.15  3.3 
Non Responder (NR) tumours  1.97  1.37  -30.2 
  1.81  1.47  -18.9 
  1.60  1.23  -22.8 
  1.07  1.23  15.3 
Median values R tumours  1.27  1.45  10.9 
Median values NR tumours  1.71  1.30  -20.8 
 
Table 2. Individual and median values of ELX2/1 at day 0 and day +2. Percentage delta of 
ELX2/1 was also calculated. Three out of 4 non responder (NR) tumours showed at day 0 higher 
values than responder (R) tumours, with a decrease at day +2. On the contrary, all R tumours 
showed an increase in ELX2/1 values from day 0 to day +2.   15
 
Fig.3. Relationship between growth percentage delta at day +14 and percentage delta of ELX2/1 
at day +2 in the treatment group, comparing responder (blue circles) and non responder tumours 
(green circles). A decrease in ELX2/1 values at day +2 with respect to day 0 was evident in 3 out 
of 4 non responder tumours whilst all responder tumours showed an increase in ELX2/1 values. 
 
At day +14, responder tumours showed ELX2/1 values comparable to the vehicle group (1.04, 
0.70-1.32 and 1.09, 0.75-1.35) whilst non responder tumours showed higher values (1.46, 1.10-
1.74). 
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Western-Blot 
Western  blot  analysis  for  VEGFR2  and  phospho-ERK  were  performed  for  16  tumor 
slices (and for the cell line) at necropsy. Two mice of the treated group and one of the vehicle 
group were not included in the western-blot analysis because of the impossibility to analyze 
more  than  9  bands  at  the  same  time.  All  the  results  are  listed  in  Table  3.  Concerning  both 
VEGFR2 and both phospho-ERK, no statistical difference was found between the treatment and 
the vehicle group and between responder and non responder group. Nevertheless, non responder 
group  showed  higher  values  of  VEGFR2  and  phospho-ERK  than  both  responder  and  both 
vehicle group. 
 
  Treated group  Vehicle group 
    Non responders  Responders 
Normalized VEGFR2  4.269 (0.616-26.063)  1.043 (0.134-1.463)  1.004 (0.562-2.245) 
Absolute VEGFR2   0.200 (0.029-1.218)  0.049 (0.006-0.068)  0.054 (0.030-0.121) 
Normalized phospho-ERK  5.346 (0.570-10.646)  0.944 (0.467-1.216)  1.007 (0.362-2.153) 
Absolute phospho-ERK   0.250 (0.027-0.498)  0.044 (0.022-0.057)  0.054 (0.024-0.116) 
 
Table  3.  Results  of  quantification  of  western  blot  analysis.  Median  and  min-max  (round 
brackets) values are expressed as arbitrary units. No statistical difference was found between 
western  blot  values  among  the  three  groups  (non-responder,  responder  and  vehicle  groups). 
However, even in absence of statistical significance, probably related to the small number of 
mice  within  each  group,  higher  values  of  VEGFR2  and  phospho-ERK  were  seen  in  non 
responders group, compared with responder and vehicle group.  
   17
Group B 
Group B comprised 8 mice, 4 in the treatment group and 4 in the vehicle group. Tumour 
volume at day 0 was 1078.40 mmc (608.75-1795.07). At day +2, tumour volume was 1365.00 
mmc (1118.29-1995.15) in the treatment group and 1134.43 (1010.63-1782.15) in the vehicle 
group  with  a  growth  percentage  delta  of  15.03%  (-1.73-36.37)  in  the  treatment  group  and 
16.74% (0.72-66.02) in the vehicle group. 
ELX2/1 was 1.16 (0.90-1.48) at day 0. At day +2, ELX2/1 in the treatment group was 1.37 
(1.06-1.58) with a percentage delta of 17.76% (-20.45-76.21) whereas 1.20 (0.94-1.28) in the 
vehicle group with a percentage delta of –3.81% (-23.20-15.90) (Fig.4). No statistical difference 
was  achieved  between  ELX2/1  values  of  the  two  groups  nor  at  day  0  neither  at  day  +2. 
Nevertheless, the same trend that emerged in Group A tumours was present also in Group B 
tumours, that is the increase in ELX2/1 values from day 0 to day +2 in the treatment group and 
the decrease in the vehicle group. 
 
Figure 4. Percentage delta of ELX2/1 comparing the treatment group and the vehicle group in 
Group B.   18
DISCUSSION 
Our study demonstrated that elastosonography appears as a promising tool in the early 
prediction  of  response  to  antiangiogenic  treatment.  The  possibility  to  quantify  the  elastic 
proprieties  of  a  mass  allowed  to  improve  the  non  invasive  diagnosis  of  thyroid  and  breast 
nodules  due  to  a  higher  stiffness  of  malignant  masses  with  respect  to  benign  ones  but 
controversial results emerged concerning the liver. Possible limitations for its use in hepatic 
imaging may be related to the high frequency probes on which elastosonography is available. 
Whist the elasticity of deep lesions still remains impossible to be evaluated, the software here 
used allows to analyze lesions located until 10 cm in depth. Thus, the majority of focal liver 
lesions may be studied through an accurate selection of the scan approach. The second limitation 
is related to the software itself, which implies the comparative analysis between the lesion and 
the surrounding parenchyma. The aim of the software is not only to measure the compression 
induced in the tissue, which involves uniquely a change in dimension, but rather the deformation, 
which involves a change in shape. The elastosonographic images are created on the basis of 
modifications of radiofrequency signals during the compression and the release of the probe, by 
comparing the deformation of a structure with the surrounding tissue included in a ROI. Thus, 
the analysis is relative and not absolute. Liver parenchyma may be affected by several conditions 
which result in change of stiffness, mainly related to fibrosis deposition. Conditions other than 
fibrosis  may  affect  reliability  of  the  results,  too.  Among  these,  some  authors  reported  the 
influence of cholestasis or right heart failure on Transient Elastography results but no data are 
actually available concerning elastosonography. HCC arises in the majority of cases on cirrhosis, 
a  condition  in  which  Fibroscan  values  range  from  12-14  kPa  to  75  kPa  (the  higher  value 
provided by the device), reflecting the dynamic fibrosis process. For these reasons, absolute 
elastosonography values of focal liver lesions derived from different patients are not comparable 
at present. Nevertheless, longitudinal evaluation of a lesion can be performed, whichever the 
baseline value.    19
  Antiangiogenic therapies are significantly burdened by treatment-related adverse events. 
The  overall  incidence  in  the  SHARP  trial  was  80%  in  the  sorafenib-group  and  52%  in  the 
placebo-group,  mainly  gastrointestinal  and  dermatologic  events  or  constitutional  symptoms.
2 
Furthermore, an upregulation of alternative pro-angiogenic signalling circuits is possible during 
the treatment. Even in presence of an initial response, the tumour vasculature may be restored, 
indicative  of  a  re-initiation  of  tumour  angiogenesis.    Interestingly,  in  a  mouse  model  of 
pancreatic neuroendocrine cancer, higher levels of mRNA for pro-angiogenic factors were found 
in relapsing tumours than in controls, suggesting the occurrence of resistance to or evasion of the 
anti-VEGF treatment.
25 These factors, beyond the high costs of such drugs, encourage the search 
for  a  marker  of  tumour  response  in  order  to  early  switch  the  patients  to  more  effective 
therapeutic regimens. 
  In our experiment, treated tumours showed an early increase in elasticity compared to 
vehicles, probably related to angioarchitectural changes inside the tumour. A possible underlying 
reason may be a reduction in tumour perfusion during the treatment. Indeed, a relative decrease 
in liquid content allows a higher deformation of a mass, which leads to a higher elasticity. 
Among treated tumours, we noted that non responders showed  a different behaviour over time 
with  respect to responders, that is higher elasticity at D0 and lower elasticity at D2. A possible 
explanation may be a strong cellularity before the treatment (responsible of higher elasticity 
values), then relatively decreased during the first days of treatment, and successively gone back 
to high levels.  
The slight decrease over time of elasticity in the vehicle group may be the expression of the 
progressive tumorigenesis process. Indeed, newly formed vessels are characteristically dilated 
and microhemorrhaging, a condition that may result in a decrease of elasticity caused by the 
lower deformation of fluids if placed in a container. 
The discrimination between responder and non-responder tumours is supported by western-blot 
analysis,  which  confirmed  the  higher  VEGFR2  and  phospho-ERK  values  in  non  responders   20
compared to responders. Even if the statistical significance was not reached, a higher expression 
of phospho-ERK and VEGFR2 may reflect the activation of this pathway of cell proliferation 
even  in  presence  of  sorafenib.  Furthermore,  tumour  volumes  at  day  +14  were  comparable 
between the non responder and the vehicle group. 
The variability of treatment response in our work is related to the genetic type of the 
animal strain used. Indeed, we preferred to perform our experiment on outbred mice who are 
tipycally characterized by a high degree of heterozygosity and heterogeneity.
26 
Our results need to be validated in clinics. Being a proof of concept study, we decided to use a 
heterotopic model in order to avoid any confounding factor derived from the small dimension of 
the  murine  liver  with  respect  to  the  probe  and  from  the  manual  compression.  Indeed,  the 
compression on humans is performed through the intercostals spaces, a condition impossible to 
be created in a murine model using the commercially available elastonography probes. 
  In conclusion, we supported the use of elastosonography in the early evaluation of tumour 
response to antiangiogenic treatments, proving that responder tumours are characterized by an 
early increase in elasticity. The possibility to distinguish a priori between responders and non 
responders based on the higher elasticity of the latter needs to be validated in ad-hoc experiments 
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